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generated based on the not-edited auto-contours. These plans were 
than evaluated on the edited auto-contours by two different 
observers.   
Results: Atlases used for auto-segmentation should carefully be 
selected, and validated in great detail to reach the most accurate 
segmentations. Compared to the use of a single-subject atlas, 
application of a multi-subject atlas improved the accuracy of the 
auto-contours. In the clinical validation study, an expert panel scored 
all auto-contours as ‘minor deviation, editable’ or better.  Compared 
to manual contouring, editing auto-contours reduced the hands-on 
time from 180 to 66 minutes. The dosimetric study showed that 
editing of auto-contoured neck CTV was inevitable to avoid (large) 
underdosages in the target, even when differences between the auto-
contoured and edited structures were small. For salivary glands, the 
necessity of editing the auto-contours was less pronounced.  
Currently we are using ABAS for auto-segmentation for most 
treatment sites (head-and-neck, neurology, lung, prostate, breast). 
ABAS is also used for adaptive treatments, when a patient needs a 
new CT due to anatomical changes. By using the initially segmented 
CT set as atlas, a high-quality structure set can automatically be 
generated for the new CT in very short time, hardly needing any 
manual editing of the contours. To realize a high throughput of ABAS, 
and to minimize human errors in its use, we developed an interface to 
run ABAS in a semi-automated way. 
Conclusions: Multi-atlas based auto-contouring of CTV images proved 
to be a very useful tool for rapid delineation of target volumes and 
normal tissues. Although editing of auto-contours is inevitable, 
especially for the target, a substantial time reduction is achieved 
when editing auto-contours, instead of manually contouring from 
scratch.  
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If the radiation-induced fibrotic (RIF) process involves irradiated 
tissues and organs, it is only highly symptomatic in some sparse 
delayed and irreversible local sequelae. Severity often depends on 
treatment-related factors, as radiotherapy dose-volume, combined 
chemotherapy, or combined major surgery (hematoma-lymphedema-
infection), and/or patient’s co-morbidities. There is a 
histopathological heterogeneous patchwork comprising concomitant 
active cellular areas and sclerotic matricial areas, describing a 
defective healing with overwhelmed defenses mechanisms [1]. 
Therapeutic clinical experience is dependent on the severity of 
radiation-induced fibrosis at baseline, the quality of clinical 
assessment (best scoring), the availability of effective drugs, and 
sufficient treatment duration (minimum 6 months) for a chronic 
disease (quality of trial design). Management of radiation-induced 
sequelae should include: reduction of co-morbidity factors, plus 
control of any acute inflammation (infection, traumatism..) that 
worsens the underlying injury, plus use of antifibrotic agents [2], and 
promotion of tissue regeneration.  
For moderate cases, medical management is based on an initial anti-
inflammatory treatment with steroids ± antibiotics (repeated for any 
acute phase) that promotes further drug penetration in the irradiated 
volume, followed by a pentoxifylline-tocopherol combination [3,4] (or 
statins) to reduce fibroproliferative “heart” sequelae, boosted by an 
organ-targeted drugs (antiseptic for enteritis, physiotherapy and 
gabapentin for neuromuscular disease,…) to control specific symptoms 
(microbial proliferation, neuromuscular irritation...).  
For severe injury including fibrosis and necrosis, management is again 
based on a first anti-inflammatory treatment; followed by vascular 
therapy (pentoxifylline, HBO, heparin, ACE inhibitors); or antifibrotic 
treatments especially PENTOCLO (combined pentoxifylline-tocopherol-
clodronate) best described in osteoradionecrosis [5]; or anticytokines 
(TGFb or TNF); and regenerative option (dead tissue removal, stem 
cell mobilization, graft). 
Controlled trials are necessary to identify useful drugs and their 
optimal combination (best strategy). However, to help patients with 
severe injuriy (pain, handicap, compression), we should always reduce 
radiation-induced fibrosis and also seek to compensate for tissue 
depletion by graft or cell regeneration, while taking into account 
organ specificities. 
  
[1] Delanian, Radiother Oncol 2004;73: 119-31;  
[2] Delanian,. Semin Radiat Oncol 2007; 1:99-107;  
[3] Delanian  J Clin Oncol 2005,23:8570-9;  
[4] Hamama, Radiother Oncol 2012, in press,.  
[5] Delanian, Int J Radiat Biol Phys 2011;80: 832-9. 
 
SP-0217   
New ideas from other discipline: Successful clinical trials in IPF 
(idiopathic pulmonary fibrosis)  
B. Crestani1 
1Hopital Bichat, Service de pneumologie, Paris, France  
 
Idiopathic pulmonary fibrosis (IPF) is the most frequent idiopathic 
interstitial lung disease. IPF is a rare and severe disease. Estimated 
annual incidence is 5/100 000 and median survival is 3 years. Diagnosis 
depends on clinical data (absence of a cause) a possible or typical 
Usual Interstitial Pneumonia (UIP) pattern on chest High Resolution 
CTscan, and a UIP pattern on lung biopsy, if performed (Raghu, Am J 
Respir Crit Care Med 2011; 183:788-824). In Europe a combination of 
prednisone, azathioprine and N-acetyl cysteine was the standard of 
care in IPF patients requiring a treatment, on the basis of the IFIGENIA 
study (Demedts, New Engl JMed 2005;353:2229-42). The IFIGENIA 
study compared the triple therapy with the combination of 
prednisone, azathioprine and placebo, and showed that the triple 
therapy reduced lung function decline. However, this triple therapy 
was recently shown to be harmful as compared to placebo (IPF clinical 
research network, NewEngl J Med 2012;366:1968-77).   
Currently pirfenidone is the only drug approved for the treatment of 
IPF. This drug is available in Japan since 2008, and in some European 
countries since 2011. The approval of pirfenidone by the European 
Medicines Agency was based upon three phase III trials, one in Japan 
(Taniguchi, Eur Respir J 2010;35:821-9), and two in European-North 
American countries (the CAPACITY trials) (Noble, Lancet 2011; 
377:1760-9).  Both studies showed that pirfenidone reduced the 
decline of lung function as evaluated by forced vital capacity. In the 
CAPACITY trials, there was also a reduction in the decline of the 6 
minutes walking distance, and a trend for an improved survival in the 
treated group. Tolerance of pirfenidone is acceptable with 
gastrointestinal (nausea, dyspepsia) and skin (photosensitivity, rash) 
side effects. The mode of action of pirfenidone is unknown. However 
pirfenidone has consistently demonstrated anti fibroticaction in 
different experimental models of lung (e.g. bleomycin-induced lung 
injury), heart, vessels and kidney fibrosis.  
Many other molecules are being evaluated in therapeutic trials in IPF. 
Nintedanib (also known as BIBF 1120) is currently being evaluated in 
two phase III trials, after a successful phase II study (Richeldi, New 
Engl J Med 2011; 365:1079-87). In that study, treatment with 
nintedanib (150mg twice daily) reduced lung function decline and 
decreased the incidence of acute exacerbation of IPF. Gastrointestinal 
side-effects requiring the cessation of the drug were observed in 
about 16% of the patients.  Nintedanib is a tyrosine kinase inhibitor 
targeting VEGFR, PDGFR, FGFR, and other kinases.  
Many more molecules are being evaluated in phase I and phase II 
studies (see www.clinicaltrials.gov). Most of these molecules are 
targeting one specific pathway among many pathways which have 
been shown to be activated in IPF and in experimental models 
ofpulmonary fibrosis. In the past, many molecules have failed (e.g. 
endothelin receptor antagonists, PDGFR antagonist, anti-TNF, 
warfarin, …). We hope that the new molecules being tested will 
finally allow for the improvement of IPF survival in the next future.  
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The transforming growth factor beta (TGF-β) signalling pathway plays 
a central role in the development of normal tissue fibrosis after 
irradiation. TGF-β is a key regulator of cell growth and 
differentiation; it affects the immune system and controls the 
homeostasis of extracellular matrix. Accordingly, mice lacking the 
TGF-β signalling intermediate Smad3 are protected from irradiation-
induced skin, liver and lung fibrosis. Moreover, knockdown of the TGF-
β/Smad3 downstream target Pai-1 protects mice from fibrosis after 
intestinal irradiation. Although radiation fibrosis has been extensively 
